---
title: "Global Health Ltd (MEDANTA) — Share Price, Financials & Analysis"
symbol: "MEDANTA"
company: "Global Health Ltd"
canonical: "https://tapetide.com/stocks/MEDANTA"
isin: "INE474Q01031"
nse_symbol: "MEDANTA"
bse_code: "543654"
sector: "Healthcare Services"
industry: "Hospitals"
market_cap_cr: 38784.18
generated_at: "2026-09-13T19:17:24.891Z"
---

# Global Health Ltd (MEDANTA)

Canonical page: https://tapetide.com/stocks/MEDANTA

## Company

- **NSE Symbol:** MEDANTA
- **BSE Code:** 543654
- **ISIN:** INE474Q01031
- **Sector:** Healthcare Services
- **Industry:** Hospitals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2022-11-16
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** medanta.org

## About

Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology.[1]

## Latest Price

- **Price:** ₹1447.2
- **Change:** -12.4 (-0.85%)
- **Open:** ₹1450.1
- **Day High:** ₹1459.7
- **Day Low:** ₹1432.3
- **Previous Close:** ₹1459.6
- **Volume:** 74678
- **As Of:** 2026-09-11T09:59:55+00:00

## Key Fundamentals

Observed at 2026-09-11T04:43:21.426833Z.

- **Market Cap:** ₹38784.18 Cr
- **Classification:** Midcap
- **P/E (reported):** 71.1
- **P/E (TTM):** 69.95
- **EPS (TTM):** ₹20.69
- **EPS (reported):** ₹17.97
- **Book Value:** ₹147.34
- **Price to Book:** 9.91
- **Dividend Yield:** 0.03%
- **ROE:** 13.91%
- **ROCE:** 15.05%
- **Debt to Equity:** 0.3
- **Revenue (yearly):** ₹4508.9 Cr
- **Net Income:** ₹554.1 Cr
- **EBITDA:** ₹1017.7 Cr
- **52-Week High:** ₹1544
- **52-Week Low:** ₹956
- **RSI (14):** 53.99

## Tapetide Score

- **Score:** 42 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 19.7 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 51.42 | 9% |
| growth | 63.29 | 9% |
| momentum | 60.3 | 12% |
| ownership | 48.24 | 24% |
| quality | 37.22 | 22% |
| valuation | 27.06 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has delivered good profit growth of 80.7% CAGR over last 5 years

### Weaknesses

- Stock is trading at 9.82 times its book value

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 14.53% | 16.72% | 129.52% |
| ebitda margin growth | 10.12% | -10.97% | -13.46% | 1.67% |
| net income growth | 11.09% | 15.13% | 19% | 81% |
| revenue growth | 10.9% | 19.56% | 18% | 25% |
| roce | 12.13% | -12.4% | -20.87% | 15.87% |
| roe | 11.01% | -2.11% | 14.86% | 14.58% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 844 | 836 | 809 | 861 | 957 | 943 | 931 | 1031 | 1099 | 1121 | 1159 | 1304 |
| Expenses | 631 | 620 | 629 | 675 | 728 | 706 | 707 | 784 | 868 | 904 | 915 | 1017 |
| Operating Profit | 213 | 216 | 179 | 186 | 228 | 238 | 225 | 247 | 231 | 217 | 244 | 287 |
| OPM % | 25 | 26 | 22 | 22 | 24 | 25 | 24 | 24 | 21 | 19 | 21 | 22 |
| Other Income | 21 | 18 | 27 | 22 | 18 | 16 | -27 | 20 | 36 | -15 | 37 | 22 |
| Interest | 20 | 18 | 18 | 18 | 16 | 16 | 15 | 14 | 17 | 22 | 27 | 27 |
| Depreciation | 43 | 44 | 45 | 47 | 49 | 48 | 49 | 45 | 50 | 61 | 67 | 69 |
| Profit before tax | 171 | 172 | 143 | 144 | 181 | 189 | 133 | 208 | 200 | 120 | 187 | 213 |
| Tax % | 27 | 28 | 11 | 26 | 28 | 24 | 24 | 24 | 21 | 21 | 24 | 26 |
| Net Profit | 125 | 124 | 127 | 106 | 131 | 143 | 101 | 159 | 158 | 95 | 142 | 157 |
| EPS in Rs | 4.66 | 4.61 | 4.74 | 3.96 | 4.87 | 5.32 | 3.78 | 5.92 | 5.89 | 3.54 | 5.36 | 5.9 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 1343 | 1456 | 1500 | 1447 | 2167 | 2710 | 3275 | 3692 | 4410 | 4683 |
| Expenses | 1218 | 1283 | 1309 | 1250 | 1709 | 2073 | 2466 | 2806 | 3480 | 3705 |
| Operating Profit | 125 | 172 | 192 | 197 | 458 | 637 | 809 | 886 | 930 | 979 |
| OPM % | 9 | 12 | 13 | 14 | 21 | 24 | 25 | 24 | 21 | 21 |
| Other Income | 49 | 50 | 44 | 31 | 39 | 49 | 75 | 29 | 98 | 80 |
| Interest | 28 | 38 | 57 | 73 | 86 | 86 | 84 | 74 | 90 | 92 |
| Depreciation | 86 | 102 | 115 | 123 | 130 | 150 | 173 | 194 | 223 | 246 |
| Profit before tax | 60 | 83 | 64 | 32 | 281 | 449 | 627 | 647 | 715 | 720 |
| Tax % | 45 | 38 | 43 | 11 | 30 | 27 | 24 | 26 | 23 | — |
| Net Profit | 33 | 51 | 36 | 29 | 196 | 326 | 478 | 481 | 554 | 552 |
| EPS in Rs | 6.78 | 10.44 | 7.36 | 5.81 | 7.75 | 12.16 | 17.81 | 17.92 | 20.7 | 20.69 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 48 | 48 | 49 | 49 | 50 | 51 | 54 | 54 | 54 | 54 |
| Reserves | 976 | 1136 | 1246 | 1300 | 1333 | 1565 | 2375 | 2852 | 3333 | 3908 |
| Borrowings | 165 | 456 | 787 | 929 | 931 | 1109 | 1122 | 802 | 718 | 1190 |
| Other Liabilities | 295 | 343 | 347 | 388 | 380 | 421 | 547 | 572 | 662 | 753 |
| Total Liabilities | 1485 | 1984 | 2430 | 2666 | 2694 | 3146 | 4097 | 4280 | 4766 | 5905 |
| Fixed Assets | 914 | 1094 | 1194 | 1703 | 1616 | 1776 | 2050 | 2236 | 2514 | 3795 |
| CWIP | 12 | 317 | 666 | 382 | 464 | 439 | 327 | 388 | 533 | 132 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Other Assets | 559 | 573 | 570 | 581 | 615 | 930 | 1720 | 1656 | 1716 | 1975 |
| Total Assets | 1485 | 1984 | 2430 | 2666 | 2694 | 3146 | 4097 | 4280 | 4766 | 5905 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 228 | 63 | 166 | 175 | 242 | 311 | 645 | 612 | 624 | 714 |
| Cash from Investing Activity | -241 | -69 | -249 | -87 | -239 | -421 | -342 | -441 | -721 | -1089 |
| Cash from Financing Activity | -7 | 9 | 97 | -1 | -81 | 160 | 346 | -514 | -97 | 272 |
| Net Cash Flow | -20 | 3 | 14 | 87 | -78 | 50 | 648 | -343 | -194 | -103 |
| Free Cash Flow | 71 | -81 | -133 | -13 | 100 | 38 | 409 | 335 | 110 | -123 |
| CFO/OP | 108 | 93 | 135 | 121 | 131 | 89 | 118 | 98 | 89 | 90 |

### Ratios

| Item | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 20 | 41 | 41 | 36 | 34 | 30 | 26 | 24 | 29 | 34 |
| Inventory Days | 28 | 26 | 26 | 43 | 42 | 36 | 35 | 32 | 28 | 29 |
| Days Payable | 92 | 124 | 142 | 147 | 138 | 90 | 114 | 90 | 81 | 89 |
| Cash Conversion Cycle | -45 | -56 | -75 | -67 | -62 | -24 | -52 | -34 | -24 | -26 |
| Working Capital Days | -23 | -33 | -18 | -31 | -48 | -20 | -37 | -32 | -21 | -7 |
| ROCE % | — | — | 6 | 6 | 5 | 15 | 17 | 20 | 20 | 17 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 33.06% | 33.05% | 33.04% | 33.04% | 33.04% | 33.03% | 33.03% | 33.01% | 33.01% | 33.01% | 33.01% | 33% |
| FIIs | 10.69% | 11.36% | 12.09% | 12.94% | 12.2% | 12.47% | 11.76% | 11.54% | 11.4% | 10.53% | 10.15% | 9.46% |
| DIIs | 10.93% | 9.68% | 10.25% | 10.57% | 11.11% | 10.51% | 11.93% | 12.2% | 12.98% | 14% | 14.77% | 16.89% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 6.85% | 6.79% | 7.14% | 6.28% | 6.54% | 6.74% | 6.53% | 6.48% | 6.03% | 5.95% | 5.88% | 5.6% |
| Others | 38.48% | 39.12% | 37.47% | 37.16% | 37.1% | 37.24% | 36.75% | 36.77% | 36.58% | 36.51% | 36.2% | 35.05% |
| No. of Shareholders | 116627 | 124775 | 166253 | 155307 | 149722 | 148633 | 154688 | 156372 | 155806 | 151241 | 147390 | 140531 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 10 / 5 / 4

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1450.82 | Sell |
| EMA (10) | 1449.98 | Sell |
| SMA (20) | 1442.55 | Buy |
| EMA (20) | 1442.23 | Buy |
| SMA (50) | 1406.53 | Buy |
| EMA (50) | 1400.72 | Buy |
| SMA (100) | 1315.89 | Buy |
| EMA (100) | 1336.55 | Buy |
| SMA (200) | 1220.04 | Buy |
| EMA (200) | 1277.95 | Buy |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 52.04 | Neutral |
| MACD (12,26,9) | 13.34 | Sell |
| Stochastic (14,3,3) | 45.96 | Neutral |
| ADX (14) | 26.43 | Buy |
| Williams %R (14) | -64.11 | Neutral |
| ATR (14) | 45.99 | High Volatility |
| ROC (12) | -0.8 | Sell |
| Stoch RSI (14) | 17.7 | Buy |
| UO (7,14,28) | 46.34 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 13 | 86.67% |
| Hold | 2 | 13.33% |
| Sell | 0 | 0% |

Based on 15 analyst ratings, observed at 2026-09-11T04:43:21.501737+00:00.

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Management to meet analysts via ICICI Securities March 24 Gurugram, March 25 Lucknow; no UPSI. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 9h - Management to meet analysts via ICICI Securities March 24 Gurugram, March 25 Lucknow; no UPSI.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/7ff44b7a-49c9-4368-a529-64842c42b8fa.pdf) |
| 8h - Medanta schedules Q4 FY2026 earnings conference call on May 15, 2026 at 2:00 PM IST, hosted by ICICI Securities. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8h - Medanta schedules Q4 FY2026 earnings conference call on May 15, 2026 at 2:00 PM IST, hosted by ICICI Securities.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/707126c3-8f86-4abf-8ff3-66dca63677b6.pdf) |
| 6 May - Board meets May 14, 2026 to approve FY26 audited results and consider final dividend. | [Board Meeting Intimation for Approval Of Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026 And Recommendation Of Final Dividend. 6 May - Board meets May 14, 2026 to approve FY26 audited results and consider final dividend.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/da6fdbcd-5c16-4fbb-9a02-fc90e4be079b.pdf) |
| 6 Mar - Investor/analyst group meeting on March 16, 2026 in Gurugram, organized by Goldman Sachs (in-person). | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 6 Mar - Investor/analyst group meeting on March 16, 2026 in Gurugram, organized by Goldman Sachs (in-person).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bdbc073a-edb4-49af-a123-489c897317ad.pdf) |
| 27 Apr - Medanta to takeover 80-bed Indore cancer hospital for Rs. 30 crores under BTA. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) 27 Apr - Medanta to takeover 80-bed Indore cancer hospital for Rs. 30 crores under BTA.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/94450273-d8c4-444f-b729-598a8f660ae4.pdf) |
| 27 Apr - Medanta to takeover 80-bed Indore cancer hospital for Rs. 30 crore under BTA on April 27, 2026. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 27 Apr - Medanta to takeover 80-bed Indore cancer hospital for Rs. 30 crore under BTA on April 27, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7135161a-06ff-4c1b-9f9a-f9f233f20a33.pdf) |
| 27 Apr - Board approved BTA for 79-bed Indore cancer hospital acquisition for Rs 30 crore; completion by September 30, 2026. | [Announcement under Regulation 30 (LODR)-Meeting Updates 27 Apr - Board approved BTA for 79-bed Indore cancer hospital acquisition for Rs 30 crore; completion by September 30, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9d673e6b-f30d-44a1-9f4e-1f291f3d5a81.pdf) |
| 27 Apr - Approved BTA to acquire 79-bed cancer hospital in Indore for Rs 30 crore, adding capacity. | [Announcement under Regulation 30 (LODR)-Acquisition 27 Apr - Approved BTA to acquire 79-bed cancer hospital in Indore for Rs 30 crore, adding capacity.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bb56bd23-9f8c-4c09-a8ad-d75985029a41.pdf) |
| 26 Mar - One-to-one virtual investor meeting with Permodalan Nasional Berhad on March 31, 2026; no UPSI. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 26 Mar - One-to-one virtual investor meeting with Permodalan Nasional Berhad on March 31, 2026; no UPSI.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/57cc17f5-3a58-4678-9148-8a0f16f4b7fa.pdf) |
| 25 Mar - Medanta to lease-built ~400-bed Varanasi hospital; company investment up to Rs.550 crore; four-year completion. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 25 Mar - Medanta to lease-built ~400-bed Varanasi hospital; company investment up to Rs.550 crore; four-year completion.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c6387973-c469-48f1-9194-7cc8920110e9.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=996251f7-20d7-4761-954a-693bef425849.pdf) |
| 2026-09-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6a55f25c-266c-4c73-b69f-60684607b1c1.pdf) |
| 2026-09-03 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=912a0e97-9386-428c-930a-c04e7d7da97a.pdf) |
| 2026-09-03 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ae5a508c-6418-490b-9b9e-c605ed05c0ee.pdf) |
| 2026-08-31 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66da5ac2-d6ff-437c-975b-c2ae294fbe24.pdf) |
| 2026-08-31 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=accaff4f-cb6a-4f25-9537-6f318aadc6a9.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=07c6f957-a8a8-41d3-bcb5-8bb925d0f64e.pdf) |
| 2026-08-22 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9551a0fa-002e-426a-8228-7af8c9349916.pdf) |
| 2026-08-22 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=737cfac4-eb13-4e64-b88c-56205c4cd12c.pdf) |
| 2026-08-22 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8c37f6f4-3712-43d5-a5d1-7ff3c6894c43.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-05 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9255b641-c6d5-495e-8026-da22a8b7c54d.pdf) |
| 2026-05-20 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c1fd981a-a599-4f3b-94b5-75f72a37ace2.pdf) |
| 2026-02-09 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=641cd536-0635-4c04-baa1-dcae9e1ba0e9.pdf) |
| 2025-08-15 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fc62db92-8713-4004-9c6b-57830fb77537.pdf) |
| 2025-05-21 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e325d495-db50-4e62-b1fc-0aed9bf6a610.pdf) |
| 2025-02-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d41a7375-57f9-47e8-abc1-f096cd04a1f3.pdf) |
| 2024-11-21 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9babd524-8cf0-4e25-bf9c-80e0ab5e8d64.pdf) |
| 2024-08-16 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=986d646e-6be3-44da-b413-337036b78d6b.pdf) |
| 2024-05-25 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2bc92434-5955-4df7-be3a-f53cd8d42bee.pdf) |
| 2024-02-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ece37d55-5d88-4d28-bd6e-b5247c744998.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-07-31 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8d0fb7c9-c6d5-49f9-8405-d1173470f1f1.pdf) |
| 2026-05-15 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=051667a3-039b-4dad-a501-a8bedeccd2c5.pdf) |
| 2026-02-05 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f5562a40-10d1-4ca5-839a-6100ad2261da.pdf) |
| 2025-11-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=81fff0c8-c689-4344-9482-abb2283f188b.pdf) |
| 2025-08-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=31aff472-7c2c-4f15-983c-e48f1dae155d.pdf) |
| 2025-05-16 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8e735e33-9efd-4f26-b198-524a16ba61b8.pdf) |
| 2024-11-14 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9281657c-77ef-490c-86c4-3c2fe571463a.pdf) |
| 2024-08-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=19161868-8107-4515-b64a-bcb3650c4f37.pdf) |
| 2024-05-20 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b7733712-18e0-4cdc-9aa5-c2003fb70008.pdf) |
| 2024-02-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aaf0af88-1327-4adb-8ab5-eeb377249b0e.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-30 | [Result For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=34bb1152-208c-4b35-95c2-be1e50dcdc58.pdf) |
| 2026-05-14 | [Board Meeting Outcome For Intimation Of Audited Financial Results.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a1230703-71a0-4be0-a384-7f8a4b7a5659.pdf) |
| 2026-02-04 | [Financial Results For Third Quarter And Nine Months Ended December 31 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db699c75-30e7-4bfa-aacc-8619682c718f.pdf) |
| 2025-11-07 | [Results For The Quarter & Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2e4a3349-978c-483e-8335-ca2ac575f5d3.pdf) |
| 2025-08-07 | [Results For The Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5ec937a9-b8ae-4b4b-8a12-a9739c782cf2.pdf) |
| 2025-05-23 | [Declaration Under Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0358337c-b6e0-4815-8295-e7c5fb0fb5dc.pdf) |
| 2025-05-15 | [Results For The Quarter And Financial Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=40c6e5d2-5ebc-4dfa-9772-dff65189d006.pdf) |
| 2025-02-04 | [Unaudited Standalone And Consolidated Financial Results For Third Quarter And Nine Months Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=243d4b7e-de26-48c0-9322-1aa71cfd3444.pdf) |
| 2024-11-14 | [Results For The Quarter And Half Year Ended Sep 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=485a3d0e-f8a2-4b2c-a542-11595c0afadf.pdf) |
| 2024-08-08 | [Financial Results For Q1 June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a0467643-fdf8-4d75-9ba2-1d1f58213955.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-07-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=93627dce-b2f4-4632-a837-6a786e65876b.pdf) |
| 2026-05-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=982eefb5-7662-498f-872e-628b1eb7289c.pdf) |
| 2026-02-04 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=671e9c31-e50a-4a7c-8e76-035eec62403f.pdf) |
| 2025-11-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3cba293c-0bbe-48aa-926e-bb35585c2505.pdf) |
| 2025-08-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=522523ba-0b14-4235-beb5-5290db200bb5.pdf) |
| 2025-05-16 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b8fc6656-c41c-48c7-9ae8-dfd0ccaf7b23.pdf) |
| 2025-05-15 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=86b4a986-f010-402f-ae57-7a54e7e2fade.pdf) |
| 2025-02-04 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7ec71e6c-cc89-4793-8dd8-bb9d19d70422.pdf) |
| 2024-11-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=100c0d3b-f5e6-4303-9d54-36bb3610e2ac.pdf) |
| 2024-08-08 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=824e6c25-f718-49a4-8ba2-d29323380daa.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=14999192-6278-44d6-b6df-03d41c7ef1f6.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/14999192-6278-44d6-b6df-03d41c7ef1f6.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9babd524-8cf0-4e25-bf9c-80e0ab5e8d64.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1594edca-3211-48d6-ad6a-61239213099b.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c1fd981a-a599-4f3b-94b5-75f72a37ace2.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/c1fd981a-a599-4f3b-94b5-75f72a37ace2.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/982eefb5-7662-498f-872e-628b1eb7289c.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/982eefb5-7662-498f-872e-628b1eb7289c.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/86b4a986-f010-402f-ae57-7a54e7e2fade.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e325d495-db50-4e62-b1fc-0aed9bf6a610.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/abbcefa8-6156-4dd1-9714-a21c86379f8b.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/33a4f194-472d-42b3-945b-5b0bef5ced8d.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:17:24.891Z.